Improved glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes and metabolic syndrome treated with liraglutide

VernacularTitle:利拉鲁肽改善新诊断2型糖尿病伴代谢综合征患者的血糖及心脏代谢危险指标
Author: Qiong-Ge ZHANG ¹ ; Chao-Qun WANG ; Hai-Yan CHEN ; Fei YE ; Yi BAO ; Yong-Quan SHI ; Jiao-Yang ZHENG
Author Information

1. 第二军医大学长征医院内分泌科
Keywords: typ2 diabetes; metabolic syndrome; liraglutide; metformin; cardiometabolic risfactors
From: Chinese Journal of Clinical Medicine 2017;24(2):229-232
CountryChina
Language:Chinese
Abstract: Objective:To discuss the effect of liraglutide on glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes (T2DM) and metabolic syndrome (MS).Methods:Sixty-three cases with newly diagnosed T2DM (HbA1c 7.5%-11%) and MS were selected, and randomly divided 1∶1 into metformin group (0.85 g,oral administration, two times a day) and liraglutide group (1.2 mg, subcutaneous injection, one time a day).The primary endpoint was change in metabolic parameters.Results:Sixty patients completed the study.There was a reduction in weight,body mass index,waist circumference,fasting glycemia,HbA1c, total and LDL-cholesterol, and triglycerides in both groups(P<0.01).Liraglutide was superior to metformin in reducing weight, BMI, and waist circumference (P<0.05).There was no adverse effect in two groups.Conclusions:Liraglutide is associated with improved glycemic control and reduction of cardiometabolic risk factors in newly diagnosed T2DM and the MS.